Article
Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitis
8 Feb 2023
Abstract excerpt
Current therapeutic strategies for treating nonalcoholic steatohepatitis (NASH) have failed to alleviate liver fibrosis, which is a devastating feature leading to hepatic dysfunction. Here, we integrated single-nucleus transcriptomics and epigenomics to characterize all major liver cell types during NASH development in mice and humans. The bifurcation of hepatocyte trajectory with NASH progression was conserved...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
